Psilocybin and Schedule I: Legal History and Rescheduling

Psilocybin Legal Status

74 reform bills

Psychedelic reform bills introduced across 25 states between 2019 and 2022 — growing from 5 bills in 2019 to 36 in 2022. An analytic model projects a majority of states will legalize by 2034 to 2037.

Siegel et al., JAMA Psychiatry, 2023

1970 CSA

the year and law that placed psilocybin in Schedule I with no scientific review process

8 CSA factors

applied to psilocybin by Johnson 2018: pharmacological profile inconsistent with Schedule I

Australia 2023

first national regulator to approve psilocybin for treatment-resistant depression (Nutt 2024)

Siegel et al., JAMA Psychiatry, 2023

View as image ↗

Psilocybin was not always illegal. It was first synthesized in 1958, studied extensively at Harvard and in European clinical settings through the early 1960s, and the subject of dozens of published papers before the term "Schedule I" existed. The legal history of how it became one of the most tightly restricted substances in federal law is a story of political timing rather than scientific evidence. The story of how it might be removed from Schedule I is still being written, with three separate federal pathways currently in motion.

For the full scientific and historical context on what Schedule I status means for psilocybin research and therapy, psilocybin's Schedule I status: history and controversy is the pillar article for this cluster.

How Psilocybin Became Schedule I: A 1970 Decision Driven by Politics, Not Science

The chemical history of psilocybin begins in 1958, when Albert Hofmann (the same Swiss chemist who had synthesized LSD fourteen years earlier) isolated and characterized psilocybin from Psilocybe mexicana mushrooms at Sandoz Laboratories in Basel. Within two years, clinical researchers at Harvard, including Timothy Leary and Richard Alpert (later known as Ram Dass), were conducting sessions with psilocybin in student volunteers and psychiatric patients.^[2]

The 1960s research era was genuinely productive. More than 40 peer-reviewed papers were published on psychedelic-assisted therapy between 1950 and 1965. The enthusiasm was also poorly controlled by today's standards: Leary's Harvard experiments lacked the methodological rigor that would be required now, and the association of psychedelics with the counterculture made them politically toxic in ways that had nothing to do with their pharmacology.^[3]

The federal restriction came in stages. The Drug Abuse Control Amendments of 1965 placed psychedelics under federal oversight for the first time. A 1968 federal law made psilocybin and related compounds explicitly illegal to manufacture or distribute. Then the Controlled Substances Act of 1970 created the scheduling system we have today and placed psilocybin in Schedule I.^[2]

The 1970 scheduling decision was made in the context of the Nixon administration's War on Drugs, not as a dispassionate scientific evaluation. There was no formal assessment of psilocybin's therapeutic potential, no review of the clinical literature from the preceding decade, and no application of the statutory criteria that the CSA itself specifies for scheduling decisions. The historical record shows a political decision that happened to use legal infrastructure, not a scientific determination that happened to have political implications.^[2]

What Schedule I Actually Requires (and Where Psilocybin Doesn't Fit)

The Controlled Substances Act specifies three criteria for Schedule I classification. A substance must have: (1) high potential for abuse; (2) no currently accepted medical use in treatment in the United States; and (3) a lack of accepted safety for use under medical supervision. A substance that meets all three belongs in Schedule I alongside heroin and no approved medical uses.

In 2018, Johnson and colleagues published a systematic analysis in Neuropharmacology that applied all 8 statutory scheduling factors the CSA provides for the full scheduling evaluation to psilocybin, not just the summary three-criterion test.^[1] The 8 factors include considerations like actual abuse rates, the severity of dependence, and the scope of illicit trafficking.

The conclusion was nuanced but directional: psilocybin scores low on physical dependence, shows no evidence of compulsive drug-seeking behavior, has a poor reinforcement profile in animal models, and produces tolerance (meaning repeated use produces diminishing effects) rather than escalating abuse. The 8-factor analysis concluded that while psilocybin does have some abuse potential appropriate for CSA scheduling, its pharmacological profile is fundamentally inconsistent with Schedule I — and that Schedule IV would be more appropriate than Schedule I if a psilocybin medicine were approved.^[1]

The "no accepted medical use" criterion presents a separate problem. FDA breakthrough therapy designation for psilocybin in treatment-resistant depression and major depressive disorder has been granted twice. Australian regulators approved it for clinical prescription in 2023. The "no accepted medical use" criterion is becoming harder to apply when other peer regulators have accepted it.

The 30-Year Research Shutdown, and Why It Is Ending

Schedule I classification does not technically prohibit research. It requires researchers to obtain a Schedule I Researcher registration from DEA, work through an institution with a Schedule I license, source the substance from DEA-licensed manufacturers, and receive approval from multiple oversight bodies for each study. The administrative burden is substantially higher than for Schedule II substances.

In practice, this created a research near-silence from 1970 through the late 1990s. The modern revival began in 2006 when Roland Griffiths and colleagues at Johns Hopkins published a landmark study on psilocybin and mystical experience in healthy volunteers. This initiated the current wave of clinical research, which has proceeded entirely under Schedule I conditions.^[3]

Siegel and colleagues documented the resulting acceleration in a 2023 JAMA Psychiatry analysis: state-level psychedelic reform bills grew from 5 in 2019 to 36 in 2022, with 25 states considering a total of 74 bills across the period. An analytical model based on marijuana legalization adoption rates projected that the majority of US states will have some form of psychedelic legalization by 2034 to 2037.^[7]

The state-federal divergence is now significant. Several states and dozens of cities have decriminalized or created access frameworks for psilocybin while federal Schedule I status remains unchanged. This creates a situation where state law permits activities that federal law prohibits, a conflict that can only be resolved at the federal level.

Three Pathways to Rescheduling (and Their Current Status)

Three distinct federal mechanisms could reschedule psilocybin. They have different timelines, different probabilities, and different implications for what rescheduled psilocybin would look like in practice.

Pathway 1: FDA Drug Approval (Most Concrete Timeline)

When the FDA approves a drug containing a Schedule I substance, the DEA is legally required to reschedule that substance within 90 days to accommodate the approved medical use. This is the most direct and legally certain rescheduling mechanism.

COMPASS Pathways, a UK-based company, is the furthest along in the regulatory process. Their Phase 2b trial (N=233, conducted across 22 sites in 10 countries) found that a single 25mg psilocybin dose produced a highly statistically significant reduction in depression scores at 3 weeks (p<0.001) compared with a 1mg control dose — the largest controlled trial dataset published to date for psilocybin in treatment-resistant depression.^[8] COMPASS has publicly targeted 2026 for a New Drug Application (NDA) submission to FDA. If approved, psilocybin would likely be rescheduled to Schedule II, which permits physician prescribing and is the classification for other controlled medical substances including certain opioids and stimulants.

The limitation of this pathway is scope: it would reschedule psilocybin only for the approved indication and drug formulation, not for general research or other therapeutic applications. Other uses would remain subject to the existing Schedule I framework or require separate approvals.

For a detailed look at what the FDA breakthrough therapy designation means and how it relates to the NDA pathway, breakthrough therapy designation and psilocybin covers the regulatory mechanism.

Pathway 2: DEA Administrative Petition (Active as of 2025)

Any person or organization can petition the DEA to initiate rescheduling proceedings for any controlled substance. The petition triggers a formal scientific and medical review by the Department of Health and Human Services (HHS), which then makes a binding recommendation to DEA. DEA must follow the HHS recommendation or provide scientific justification for departing from it.

In August 2025, Dr. Sunil Aggarwal and the Advanced Integrative Medical Science Institute filed a petition with DEA specifically requesting rescheduling of psilocybin. The petition is currently under HHS review. DEA has also substantially increased its annual psilocybin production quota for 2026 (per DEA Federal Register, 2025), a logistical signal of anticipated research and potentially clinical demand.

The administrative petition pathway bypasses the pharmaceutical approval process entirely, which is significant: a successful petition could reschedule psilocybin broadly rather than for a specific approved drug. The timeline is less certain than the FDA pathway, and the scientific evidence base assembled by Johnson and colleagues in 2018 provides the formal academic argument supporting petition success.^[1]

Pathway 3: Congressional Legislation (Slowest, Most Uncertain)

Congress has the authority to amend the CSA directly. Several bills have been introduced at the federal level: the Freedom to Heal Act (sponsored by Senator Booker and others) would establish a framework for psychedelic-assisted therapy; Senate Joint Resolution 10 has addressed psilocybin access more specifically.

Congressional action has historically been the slowest pathway for drug scheduling reform. The state-level momentum documented by Siegel 2023 creates political pressure, but federal legislative timelines are measured in years and subject to broader political dynamics unrelated to the scientific evidence.^[7]

What Moving to Schedule II or Schedule IV Would Actually Mean

Rescheduling is not a single outcome. The schedule psilocybin enters determines the practical implications for research, clinical access, and insurance coverage.

Schedule II contains substances with accepted medical use but high abuse potential, including certain opioids, stimulants, and cocaine (used as a local anesthetic). Schedule II status would allow physicians with DEA registration to prescribe psilocybin. Researchers would face dramatically reduced administrative barriers compared to Schedule I. Production quotas would still exist but would be set to accommodate clinical demand.

Schedule III or IV status would represent a more significant reduction in controls. Schedule IV substances, including benzodiazepines and certain sleep medications, have broader prescribing authority and face fewer research restrictions. Insurance coverage for scheduled substances tends to improve as the schedule number increases.

Schonholz and colleagues (2024) analyzed the collision between Schedule I status and emerging psilocybin clinical practice, noting that after any rescheduling, significant challenges remain around equity of access, insurance coverage requirements, and the standard-of-care implications for physicians who have been using psilocybin in legal gray zones under state decriminalization frameworks.^[5] The "respectable minority doctrine" in medical law (which protects physicians whose practice, while uncommon, reflects a recognized minority of professional opinion) is one legal mechanism that has been applied to physicians involved in psilocybin therapy even under Schedule I, but rescheduling would substantially change that legal calculus.

Australia's Approval: The Strongest Challenge to "No Accepted Medical Use"

In 2023, Australia's Therapeutic Goods Administration (TGA) approved psilocybin for prescription use in treatment-resistant depression. This made Australia the first national drug regulator to recognize psilocybin as having an accepted medical use, the specific finding that directly undermines the central Schedule I criterion.^[4]

Nutt and colleagues documented the significance of this decision and its international implications in a 2024 review in the British Journal of Pharmacology. Australia's TGA acted on the same clinical evidence base that exists for US regulators: primarily the Phase 2b COMPASS data and the Johns Hopkins depression trials. The decision demonstrates that a sophisticated regulatory agency with access to the same research concluded that accepted medical use exists.^[4] The "no accepted medical use" criterion becomes harder to sustain when peer regulators disagree.

What implementation actually looks like matters too. Dutton and colleagues (2026) documented the practical challenges that followed Australia's approval: prescriber training was insufficient for the demand, informed consent processes were more complex than anticipated, and insurance coverage remained limited. The Australian experience provides both a proof of concept for rescheduling and a clear warning that regulatory approval alone does not create a functional clinical system.^[6]

For a deeper look at the Australian regulatory decision and what it means for the US debate, Australia's TGA approval: the first country to prescribe psilocybin covers the decision in detail.

Has Any Drug Been Moved Off Schedule I Before?

The precedent for removing a substance from Schedule I exists, though examples are limited. CBD (cannabidiol) effectively exited Schedule I classification through the 2018 Farm Bill, which removed hemp-derived CBD from the CSA's definition of marijuana. Ketamine was never placed in Schedule I when it became available clinically, demonstrating that regulators can place drugs with psychoactive properties in less restrictive schedules when medical use is demonstrated.

The most relevant recent precedent is the ongoing federal marijuana rescheduling process, which demonstrated both that rescheduling is legally possible and that it is politically complex and slow even when scientific consensus points in a clear direction.

The legal framework for rescheduling is established. The scientific argument, summarized systematically by Johnson and colleagues in 2018 and supported by multiple high-quality clinical trials, is more developed for psilocybin than it was for any substance that has previously gone through this process.^[1] What remains uncertain is not whether the scientific case exists but which pathway delivers rescheduling first, and on what timeline.

The Bottom Line

Psilocybin's Schedule I status originates from a 1970 political decision rather than a scientific evaluation. A 2018 systematic analysis applying all 8 statutory CSA factors found psilocybin's pharmacological profile inconsistent with Schedule I, recommending Schedule IV as more appropriate if approved as medicine. Three federal pathways exist toward rescheduling: FDA drug approval (COMPASS Phase 2b trial shows p<0.001 for 25mg vs. control at 3 weeks; NDA publicly targeted for 2026), the August 2025 DEA administrative petition currently under HHS review, and Congressional legislation. Australia's 2023 regulatory approval provides the clearest international challenge to the "no accepted medical use" criterion. The scientific case for rescheduling is established. The timing depends on which pathway moves first.

Frequently Asked Questions

How did psilocybin become a Schedule I drug?

Psilocybin was placed in Schedule I under the Controlled Substances Act of 1970 during the Nixon administration's War on Drugs. The decision was not preceded by a formal scientific evaluation of psilocybin's therapeutic potential or a systematic review of the 1960s clinical literature. Nichols (2020) and Geiger (2018) both document the politically motivated nature of the scheduling decision.

What does rescheduling psilocybin mean?

Rescheduling means moving psilocybin from Schedule I (no accepted medical use, highest restrictions) to a lower schedule. Schedule II would allow physician prescribing and ease research requirements; Schedule III or IV would reduce controls further. Rescheduling would not make psilocybin freely available. It would remain a controlled substance, but one that licensed physicians could prescribe and researchers could study with fewer administrative barriers.

What is the DEA rescheduling process for psilocybin?

The DEA receives a rescheduling petition and forwards it to the Department of Health and Human Services (HHS) for a scientific and medical evaluation. HHS makes a binding recommendation, which DEA must follow or explain scientifically why it disagrees. An August 2025 petition filed by Dr. Sunil Aggarwal and the AIMS Institute is currently under HHS review. This pathway runs parallel to the FDA drug approval track.

What schedule would psilocybin move to if rescheduled?

Most analysis suggests Schedule II as the most likely destination through the FDA drug approval pathway, since Schedule II accommodates substances with accepted medical use but significant control requirements (including opioids and stimulants). A DEA administrative petition could potentially result in a lower schedule. The specific outcome depends on which pathway produces rescheduling and what evidence HHS or FDA relies on. Schonholz et al. (2024) notes that schedule placement has significant implications for insurance coverage and prescribing access.

When could psilocybin be rescheduled?

The most concrete timeline runs through COMPASS Pathways' NDA submission publicly targeted for 2026. If FDA approves, DEA must reschedule within 90 days, placing the most optimistic scenario in 2027. The August 2025 DEA administrative petition has a less certain timeline: HHS review typically takes 1-2 years. Congressional action has no predictable timeline. The state-level momentum documented by Siegel et al. (2023) — 74 state bills across 25 states, with an analytic model projecting majority-state legalization by 2034 to 2037 — creates political pressure but does not directly accelerate federal timelines.

Has any drug been moved off Schedule I before?

Yes. CBD (cannabidiol) effectively exited Schedule I classification through the 2018 Farm Bill for hemp-derived versions. Ketamine was never placed in Schedule I when approved for treatment-resistant depression, establishing that regulatory bodies can place psychoactive compounds in less restrictive schedules when medical use is demonstrated. The ongoing federal marijuana rescheduling process demonstrates both that rescheduling is legally possible and that it is politically complex even with strong scientific support.

Sources & References

1. 1RTHM-00514·Johnson, Matthew W et al. (2018). “The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act..” Neuropharmacology.Study breakdown →PubMed →↩
2. 2RTHM-00646·Nichols, David E (2020). “Psilocybin: from ancient magic to modern medicine..” The Journal of antibiotics.Study breakdown →PubMed →↩
3. 3RTHM-00509·Geiger, Haden A et al. (2018). “DARK Classics in Chemical Neuroscience: Psilocybin..” ACS chemical neuroscience.Study breakdown →PubMed →↩
4. 4RTHM-00898·Nutt, David J et al. (2024). “The Australia story: Current status and future challenges for the clinical applications of psychedelics..” British journal of pharmacology.Study breakdown →PubMed →↩
5. 5RTHM-01983·Schonholz, Stephanie M et al. (2024). “Legal and Ethics Concerns of Psilocybin as Medicine..” The journal of the American Academy of Psychiatry and the Law.Study breakdown →PubMed →↩
6. 6RTHM-00958·Dutton, Megan et al. (2026). “Psilocybin in the real world: Regulatory, ethical, and operational challenges in Australia's clinical landscape..” The Australian and New Zealand journal of psychiatry.Study breakdown →PubMed →↩
7. 7RTHM-01791·Siegel, Joshua S et al. (2023). “Psychedelic Drug Legislative Reform and Legalization in the US..” JAMA psychiatry.Study breakdown →PubMed →↩
8. 8RTHM-00761·Goodwin, Guy M et al. (2022). “Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression..” The New England journal of medicine.Study breakdown →PubMed →↩